BRITISH COLUMBIA, Canada--(BUSINESS WIRE)--InNexus Biotechnology Inc. (OTCBB:IXSBF - News) (TSX VENTURE:IXS - News), a drug development company commercializing the next generation of monoclonal antibodies based on its Dynamic Cross Linking (DXL™) technology, will host an operational update teleconference on November 8th at 11:00 AM ET to discuss fiscal year 2007 and ongoing operations including the pre-clinical program of its lead product, DXL625 (CD20).
